• GLP-validated, high-throughput, 3D-bioprinted platforms for relevant toxicological and pharmacological endpoints
  • Quantitative in vitro-in vivo extrapolation (QIVIVE): what in vivo phenotype is your in vitro system relevant for, and how much?”
  • Characterisation of the mechanism of action (MOA) of exposures. Relevant for DESIGN of new compounds! (TOXICOGENOMICS)
  • Selection of relevant positive/negative chemical test items via AI-based computational approaches (QSAR, read-across, virtual screening)